Barclays Downgrades Thermo Fisher Scientific to Equal-Weight, Raises Price Target to $555
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Luke Sergott has downgraded Thermo Fisher Scientific (TMO) from Overweight to Equal-Weight but increased the price target from $475 to $555.

January 24, 2024 | 12:54 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Barclays downgraded Thermo Fisher Scientific to Equal-Weight but raised the price target to $555, indicating mixed sentiment.
The downgrade to Equal-Weight suggests that Barclays sees limited upside potential for TMO, aligning it with the market performance expectation. However, the increase in the price target to $555 implies a positive view on the company's valuation, which could counterbalance the downgrade's negative impact. The mixed sentiment may lead to a neutral short-term impact on TMO's stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100